Third-Line’s A Charm: Amgen Aims To Take A BiTE Out Of Pretreated SCLC
The company presented data for its bispecific antibody tarlatamab at WCLC, drawing noticeably more excitement than highly anticipated but disappointing data for Lumakras with checkpoint inhibitors.
You may also be interested in...
Amgen's DLL3-targeting bispecific T-cell engager could be filed on Phase II data having demonstrated exceptional duration of response in small cell lung cancer patients.
Sales of the Humira biosimilar increased double digits globally year over year, but declined 63% in the US versus Q1 due to inventory stockpiling.
Deal Snapshot: Other major players have made headway in bispecifics for prostate cancer, while Jemincare’s drug is the latest China-developed technology to head westward.